steenbjere

The Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of HAE in adults and pediatric patients 12 years of age and older in Israel. “We continue to make significant progress in bringing our oral, once-daily prophylactic therapy to many HAE patients around the world,” says Charlie Gayer, [...]

TAKHZYRO® (lanadelumab), the first approved monoclonal antibody for the treatment of HAE, has been named the 2022 winner of the prestigious Prix Galien Canada Innovative Product Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation, Prix Galien Canada recognizes the efforts and achievements of pharmaceutical research and development. “We are honored [...]

KalVista Pharmaceuticals, Inc. presents two posters at the 2022 meeting of the American College of Allergy, Asthma & Immunology. The first highlighted new data that reveals the significant impact of HAE attacks on the mental health, daily activities, and quality of life for people living with HAE receiving either parenterally delivered on-demand only treatment or prophylaxis [...]

At the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting, Intellia Therapeutics, Inc. announces updated data from an ongoing Phase 1/2 clinical study of NTLA-2002 for the treatment of HAE. The data are from 10 adult patients with HAE in the Phase 1, dose-escalation portion of the study, with a data cut-off [...]

At the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, Ionis Pharmaceuticals, Inc. presents positive results from a Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational antisense medicine, donidalorsen, in patients with HAE. Interim data after all patients completed 1 year of treatment in the study showed [...]

BioCryst Pharmaceuticals, Inc. announces new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and older who started on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of HAE, including patients who switched from other prophylactic therapies. The data are being presented at the 2022 [...]

Pharvaris presents two in-person “ePoster – Meet the Author” at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2022. “The data demonstrate the optimized pharmacokinetic and tolerability profiles of Pharvaris’ drug candidates that are in clinical development for the treatment of HAE,” says Peng Lu, M.D., Ph.D., Chief Medical Officer of [...]

“We are on track to report preliminary results from our Phase 1a trial of STAR-0215 by the end of this year. The trial is assessing safety and tolerability and will inform on dosing frequency and target engagement. We believe the results from this trial will validate STAR-0215’s differentiated best-in-class profile,” says Jill C. Milne, Ph.D., [...]

At the presentation of operational highlights and financial results for the third quarter ended 30 September 2022, Intellia Therapeutics, Inc. President and CEO John Leonard, M.D., says: “During the most recent quarter, Intellia has achieved significant clinical milestones. Interim data from our in vivo program, NTLA-2002, demonstrated robust reductions in both plasma kallikrein levels and the rate [...]

“With ORLADEYO on a trajectory to more than double sales in its second year of launch after a very strong first year, we continue to demonstrate that what we are offering HAE patients is unique and fills their need for a therapy that offers both low burden of disease and low burden of treatment. We [...]